Safety of hematopoietic stem cell donation in glucose 6 phosphate dehydrogenase-deficient donors

Pilo, Federica; Baronciani, D; Depau, Cristina; Targhetta, Clara; Pani, Mario; Manconi, R; Fadda, Maurizio; Mamusa, Angela Maria; Angelucci, Emanuele

doi:10.1038/bmt.2012.112

Cited by 5 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Individuals with hemolytic anemia are suitable if the disease has been infectious-or drug-induced and they have fully recovered. HSC collections from individuals with RBC abnormalities such as spherocytosis and elliptocytosis are generally not recommended, whereas subjects with G6PD deficiency are eligible [48]. Individuals with thalassemia trait, mild a-thalassemia, or b-thalassemia minor are suitable, whereas donations in case of intermediate/major forms are generally not recommended.…”

Section: Suitability Criteria For Hematological Diseases and Coagulatmentioning

confidence: 99%

Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues

Worel

Buser

Greinix

et al. 2015

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

The number of allogeneic hematopoietic stem cell (HSC) transplants performed globally each year continues to increase. Advances in HLA typing, better supportive care, and administration of reduced-intensity conditioning regimens allow treatment of older patients with older sibling donors. Pretransplant donor assessment and testing are very important processes affecting the quality and safety of donation. For unrelated HSC donors detailed recommendations for health assessment have been published, allowing donation only if they are unrestrictedly healthy. Eligibility criteria for related donors are less strict and vary significantly between centers. In situations where a family donor does not meet the suitability criteria for unrelated donors, involved physicians often struggle with the decision whether the matched relative is suitable for donation or not. On behalf of the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues, we intended to develop a consensus document with recommendations for donor workup and final clearance of family donors who would not be able to serve as unrelated donors because of their age or pre-existing diseases. This article covers different topics intending to support decision-making, with the goal of minimizing medical risk to the donor and protection of the recipient from transmissible diseases.

show abstract

Section: Suitability Criteria For Hematological Diseases and Coagulatmentioning

confidence: 99%

Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues

Worel

Buser

Greinix

et al. 2015

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

show abstract

Section: Transfusion Medicine and Cellular Therapymentioning

confidence: 99%

“…Hematopoietic stem cells (HSCs) (from peripheral blood , bone marrow and umbilical cord blood ) from G6PD‐deficient donors have been successfully used for transplantation. Although data are limited, no adverse events related to granulocyte colony‐stimulating factor treatment are reported in G6PD‐deficient stem cell donors . In long‐term follow‐up studies of recipients of HSCs from G6PD‐deficient donors, there were no decreases in engraftment or survival, as compared to recipients of HSCs from normal donors .…”

Section: Transfusion Medicine and Cellular Therapymentioning

confidence: 99%

“…Although data are limited, no adverse events related to granulocyte colony‐stimulating factor treatment are reported in G6PD‐deficient stem cell donors . In long‐term follow‐up studies of recipients of HSCs from G6PD‐deficient donors, there were no decreases in engraftment or survival, as compared to recipients of HSCs from normal donors . In most cases, the recipient converts to the G6PD status of the donor ; therefore, it is important to be aware that, following engraftment, a recipient of an HSC graft from a G6PD‐deficient donor will also be G6PD‐deficient.…”

Section: Transfusion Medicine and Cellular Therapymentioning

confidence: 99%

See 1 more Smart Citation

Glucose‐6‐phosphate dehydrogenase deficiency in transfusion medicine: the unknown risks

et al. 2013

View full text Add to dashboard Cite

The hallmark of glucose-6-phosphate dehydrogenase (G6PD) deficiency is red blood cell (RBC) destruction in response to oxidative stress. Patients requiring RBC transfusions may simultaneously receive oxidative medications or have concurrent infections, both of which can induce hemolysis in G6PD-deficient RBCs. Although it is not routine practice to screen healthy blood donors for G6PD deficiency, case reports identified transfusion of G6PD-deficient RBCs as causing hemolysis and other adverse events. In addition, some patient populations may be more at risk for complications associated with transfusions of G6PD-deficient RBCs because they receive RBCs from donors who are more likely to have G6PD deficiency. This review discusses G6PD deficiency, its importance in transfusion medicine, changes in the RBC antioxidant system (of which G6PD is essential) during refrigerated storage, and mechanisms of hemolysis. In addition, as yet unanswered questions that could be addressed by translational and clinical studies are identified and discussed.

show abstract

“…If the donor had glucose-6-phosphate dehydrogenase enzyme deficiency, the recipient might benefit from counseling about this condition. However, neither condition is a contraindication to stem cell donation in a patient with hemoglobinopathy [6,7].…”

Section: Introductionmentioning

confidence: 99%

Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT

Shenoy

Gaziev²,

Angelucci³

et al. 2018

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Allogeneic hematopoietic cell transplantation (HCT) can halt organ damage and eliminate symptoms in hemoglobin disorders, including sickle cell disease (SCD) and thalassemia major. Managing the residual manifestations of pre-HCT disease complications and the long-term effects of HCT requires systematic monitoring, follow-up and intervention when indicated. Late complications vary with age and disease status at HCT and with transplant variables such as preparative regimen, donor source and compatibility, and immune reconstitution. An international consensus conference sponsored by the Pediatric Blood and Marrow Transplant Consortium in May 2016 entitled "Late Effects Screening and Recommendations Following HCT for Immune Deficiency and Nonmalignant Hematologic Disorders" focused on follow-up after HCT for hemoglobinopathy. An earlier publication from experts who participated in this session described the pathophysiology and spectrum of complications that HCT recipients experience after HCT for SCD and thalassemia major. This companion publication summarizes the consensus reached by this group of experts about long-term follow-up guidelines after HCT for hemoglobinopathy. In addition, these guidelines might also be included in studies of novel curative therapies such as autologous HCT after hematopoietic progenitor stem cell gene modification.

show abstract

Safety of hematopoietic stem cell donation in glucose 6 phosphate dehydrogenase-deficient donors

Cited by 5 publications

References 10 publications

Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues

Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues

Glucose‐6‐phosphate dehydrogenase deficiency in transfusion medicine: the unknown risks

Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT

Contact Info

Product

Resources

About